The health data platform developed and maintained by Seer Inc is intended to facilitate early, pre-symptomatic detection of chronic life-threatening diseases. The effort is to capture and translate molecular insights from the proteome with improved accuracy and speed, enabling healthcare professionals to detect cancer and neurological diseases, drive earlier treatment and improve patient outcomes. A life sciences company structured around capturing deep molecular insights from the proteome to enable novel insights and breakthroughs in the understanding of biology and disease, Seer Inc's novel Proteograph™ platform allows for the first-ever generation of proteomic information having high accuracy at a scale and a speed not previously possible. Working in complementary manner with genomic and other health information the objective is to enable research breakthroughs in taraes like as early detection of disease. The firm is advancing a portfolio of first-in-class products for research and clinical applications. With the technology the firm brings to the table utilizable withthatf otherfirm,the effort is to form strategic relationships with various players inthe space oin support of their efforts in the drug discovery and development space.
